Literature DB >> 25794608

Preparation and characterization of azithromycin--Aerosil 200 solid dispersions with enhanced physical stability.

Xuechao Li1, Huanhuan Peng1, Bin Tian1, Jingxin Gou1, Qing Yao1, Xiaoguang Tao1, Haibing He1, Yu Zhang1, Xing Tang1, Cuifang Cai2.   

Abstract

The main purpose of this study was to investigate the feasibility of azithromycin (AZI)--Aerosil 200 solid dispersions specifically with high stability under accelerated condition (40 °C/75% RH). Ball milling (BM) and hot-melt extrusion (HME) were used to prepare AZI solid dispersions. The physical properties of solid dispersions were evaluated by differential scanning calorimetry (DSC), scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR) and thermogravimetric analysis (TGA). For solid dispersions prepared with both methods, no crystalline of AZI was detected (except for AZI: Aerosil 200=75:25) by DSC or PXRD, indicating the amorphous state of AZI in solid dispersions. The FT-IR results demonstrated the loss of crystallization water and the formation of hydrogen bonds between Aerosil 200 and AZI during the preparation of solid dispersions. After 4 weeks storage under accelerated condition, the degree of crystallinity of AZI increased in solid dispersions prepared by BM, whereas for solid dispersions containing AZI, Aerosil 200 and glyceryl behenate (GB) prepared by HME, no crystalline of AZI was identified. This high stability can be attributed to the hydrophobic properties of GB and the presence of hydrogen bonds. Based on the above results, it is inferred the protection of hydrogen bonds between AZI and Aerosil 200 formed during preparation process effectively inhibited the recrystallization of AZI and improved the physical stability of amorphous AZI in the presence of Aerosil 200.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosil 200; Ball milling; Hot-melt extrusion; Physical stability; Solid dispersion

Mesh:

Substances:

Year:  2015        PMID: 25794608     DOI: 10.1016/j.ijpharm.2015.03.029

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Production of a new platform based on fumed and mesoporous silica nanoparticles for enhanced solubility and oral bioavailability of raloxifene HCl.

Authors:  Jaleh Varshosaz; Ladan Dayani; Sana Pirmardvand Chegini; Mohsen Minaiyan
Journal:  IET Nanobiotechnol       Date:  2019-06       Impact factor: 1.847

2.  The inhibiting role of hydroxypropylmethylcellulose acetate succinate on piperine crystallization to enhance its dissolution from its amorphous solid dispersion and permeability.

Authors:  Yueyi Deng; Qi Liang; Yiru Wang; Xiaolan Zhang; Chengyun Yan; Yulin He
Journal:  RSC Adv       Date:  2019-12-03       Impact factor: 4.036

3.  Azithromycin-loaded linolenic acid-modified methoxy poly(ethylene glycol) micelles for bacterial infection treatment.

Authors:  Yi Wen; Zhimei Song; Hongmei Xu; Sijia Feng; Li Zhu; Fangfang Teng; Runliang Feng
Journal:  Drug Deliv Transl Res       Date:  2021-03-14       Impact factor: 4.617

4.  Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone.

Authors:  Xuyu Chai; Hongyu Chai; Xiaoyu Wang; Jingjing Yang; Jin Li; Yan Zhao; Weimin Cai; Tao Tao; Xiaoqiang Xiang
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

5.  Preparation of Azithromycin Amorphous Solid Dispersion by Hot-Melt Extrusion: An Advantageous Technology with Taste Masking and Solubilization Effects.

Authors:  Jiale Li; Conghui Li; Hui Zhang; Xiang Gao; Ting Wang; Zengming Wang; Aiping Zheng
Journal:  Polymers (Basel)       Date:  2022-01-26       Impact factor: 4.329

6.  Customized Novel Design of 3D Printed Pregabalin Tablets for Intra-Gastric Floating and Controlled Release Using Fused Deposition Modeling.

Authors:  Shrawani Lamichhane; Jun-Bom Park; Dong Hwan Sohn; Sangkil Lee
Journal:  Pharmaceutics       Date:  2019-10-30       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.